Collaboration expanded from five to seven targets and provides AbCellera the option to co-develop therapeutic programs in partnership with Empirico. Continue reading “AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration” →Continue reading →
VANCOUVER, British Columbia & SAN DIEGO, April 14, 2021 — AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration. Through each company’s proprietary technologies, the multi-target collaboration leverages hyper-scale datasets, machine learning, and advanced computation to both identify high-value, genetically-validated drug targets and discover novel therapeutic antibodies.
Continue reading “AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration” →
GENOMEWEB—Empirico said on Thursday that it has formed a drug discovery alliance with antisense therapeutics firm Ionis Pharmaceuticals.
As part of the deal, Ionis has taken a $10 million stake in Empirico, which also announced the close of a $17 million Series A-2 financing round.Continue reading →
Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeutics
SAN DIEGO, January 9, 2020 — Empirico Inc. announced today that it has entered into a strategic collaboration with Ionis Pharmaceuticals. During the three-year collaboration, Empirico will utilize its Precision Insights Platform, which incorporates huge biological data sets, human genetics and advanced algorithmic approaches, to identify therapeutic targets for indications and tissues that are amenable to Ionis’ industry-leading antisense technology.
Continue reading “Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeutics” →
ENDPOINTS NEWS—Omri Gottesman came to the US from the UK 10 years ago, wide-eyed like many others.
The human genome project was long-complete and, with great fanfare, researchers were beginning to try and leverage those insights into treatments. Mount Sinai School of Medicine offered him a fellowship focused on just that: genomic medicine. Continue reading “Ionis finds new partner in a young biotech and its hopeful founder” →Continue reading →
Xconomy San Diego —Empirico, a biotech that has developed tools to analyze genomics data and use those insights to identify potential therapeutic targets, has signed a collaboration deal with antisense drug developer Ionis Pharmaceuticals that includes a $10 million equity investment.Continue reading →
BIOWORLD—It’s a big day for privately held Empirico Inc. as it embarks on a massive combo pharma deal with Ionis Pharmaceuticals Inc. while racking up a $12.5 million series A-2 financing.
In the collaboration, Empirico will identify the targets and Ionis can advance as many as 10 of them. The two companies plan to use human genetics data in their efforts with programs Ionis already has in the works, and that includes target validation, the indication and biomarker selection, and patient stratification.Continue reading →
BIOCENTURY—Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on Thursday, designed to bring antisense therapeutics into new tissues and indications.Continue reading →